An update on advances in the technologies available for translational research. Sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies.
3:30 - 5:00
RNAi and Target Discovery - Ballroom C-1
Moderator: C. Kent Osborne, MD, Baylor College of Medicine, Houston, TX
RNAi technologies in cancer gene discovery
Thomas Westbrook, PhD
Baylor College of Medicine
Houston, TX
Breast Cancer Prevention - Ballroom C-3
Moderator: Powel Brown, MD, PhD, MD Anderson Cancer Center, Houston, TX
Options and Opportunities in Breast Cancer Prevention
Judy Garber, MD
Dana-Farber Cancer Institute
Boston, MA
Advances in Preventive Therapy
Jack Cuzick, PhD
Wolfson Institute of Preventive Medicine
London, UNITED KINGDOM
5:30 - 7:00
Technologies for Translational Research - Ballroom C-1
Moderator: Charles Perou, PhD, Lineberger Cancer Center, Chapel Hill, NC
Overview of Translational Technologies and Gene Expression Profiling
Charles Perou, PhD
Lineberger Cancer Center
Chapel Hill, NC
Sequencing of breast cancer genome
Michael R Stratton, FRCPath, FMedSci, FRS
Wellcome Trust Sanger Institute
Hinxton, UNITED KINGDOM
Technological needs for realizing the opportunities offered by personalized medicine
Gordon Mills, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
The Basics of Epigenetics, and its Biological and Clinical Relevance - Ballroom C-2
Moderator: Steffi Oesterreich, PhD, Baylor College of Medicine, Houston, TX
DNA methylation – Role in Gene Regulation, and methods to study it
Saraswati Sukumar, PhD
Johns Hopkins Oncology Center
Baltimore, MD
What is the Histone Code, and why is it important?
Steffi Oesterreich, PhD
Baylor College of Medicine
Houston, TX
Epigenetic Therapy – Past, Present, Future
Jean-Pierre Issa, MD
UT MD Anderson Cancer Center
Houston, TX
Clinical Trials 102: New Strategies in Targeted Therapy Clinical Trials - Ballroom C-3
Susan Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX
Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM
Thursday, 12/10/09
7:00 - 5:45
Registration
8:30 - 8:45
Opening Remarks - Exhibit Hall D
8:45 - 9:15
Plenary Lecture 1- Exhibit Hall D
An epidemiological perspective on the causes and prevention of breast cancer
Valerie Beral, MD
University of Oxford
Oxford, UNITED KINGDOM
9:15 - 11:30
General Session 1 (#11-19)
11:30 - 12:00
AACR Outstanding Investigator Award for Breast Cancer Research, supported by an educational grant from Susan G. Komen for the Cure®
Therapeutic Implications of the Molecular Portraits of Breast Cancer
Charles Perou , PhD
Lineberger Cancer Center
Chapel Hill, NC
12:00 - 1:35
Lunch
12:30 - 1:35
Clinical Science Forum: Controversies in Adjuvant Chemotherapy - Exhibit Hall D
Moderator: James Ingle, MD, Mayo Clinic College of Medicine, Rochester, MN
Are there groups of patients who don't benefit from chemotherapy?
Peter Ravdin, MD, PhD
UT Health Science Center
San Antonio, TX
What are the best and most highly effective chemotherapy regimens?
Eric Winer, MD
Dana-Farber Cancer Institute
Boston, MA
12:30 - 1:35
Basic Science Panel Discussions: Controversies in Breast Cancer Models for Drug Development - Ballroom B
Moderator: Lewis Chodosh, MD, PhD, University of Pennsylvania, Philadelphia, PA
Our Inner Mouse: Genomic Insights From Mouse Mammary Cancer Models to Guide Pre-clinical Testing
Jeffrey E. Green, MD
NCI
Bethesda, MD
Pre-clinical models for development of marker guided therapy in breast cancer
Laura J. van 't Veer, PhD
The Netherlands Cancer Institute
Amsterdam
12:30 - 1:35
Career Mentoring Forum: A Networking Session for Young Investigators - Ballroom A
Bring your lunch and join roundtable discussions with senior scientists who are leaders in the field! This session is open to graduate students, medical students and residents, and clinical and postdoctoral fellows. Space is limited, and pre-registration is required. Return the registration form by November 24, 2009.
Discussion topics may include grant writing, publication strategies, negotiating a job offer or promotion, oral presentation skills, setting up and managing a laboratory, working for or working with the pharmaceutical/biotech industry, how to get the most out of being a cooperative group member, the path to leading clinical trials, and balancing research and clinical practice.
1:45 - 2:45
Mini-Symposium 1 - Exhibit Hall D
Emerging use of nanotechnology in cancer diagnosis and therapy
Moderators: Jenny Chang, MD, Baylor College of Medicine, Houston, TX and Adrian Lee, PhD, Baylor College of Medicine, Houston, TX
1:45
Diagnostic and Therapeutic Applications of Nanotechnology
Jennifer West, PhD
Rice University
Houston, TX
2:15
Engineered polymeric nanoparticles for therapeutic and diagnostic application
Omid Farokhzad, MD
Brigham and Women's Hospital/Harvard Medical School
Cambridge, MA
3:00 - 4:30
General Session 2 (#21-27) - Exhibit Hall D
4:30 - 5:30
Susan G. Komen for the Cure Brinker Awards for Scientific Distinction Lectures - Exhibit Hall D
5:30 - 7:30
Poster Discussion 1 (#101-111) - Ballroom A
5:30 - 7:30
Poster Discussion 2 (#201-208) - Ballroom B
5:30 - 7:30
Poster Session 1 (#1001-1167) - Exhibit Hall A-B
Friday, 12/11/09
6:45 - 5:45
Registration
7:00 - 9:00
Poster Discussion 3 (#301-308) - Ballroom A
7:00 - 9:00
Poster Discussion 4 (#401-410) - Ballroom B
7:00 - 9:00
Poster Session 2 (#2001-2166) - Exhibit Halls A-B
9:00 - 9:30
Plenary Lecture 2
Target the PI3K/AKT/mTOR pathway in cancer
William Sellers, MD
Novartis Institutes for Biomedical Research, Inc.
Cambridge, MA
9:30 - 11:30
General Session 3 (#31-38) - Exhibit Hall D
11:30 - 12:00
AACR Distinguished Lectureship in Breast Cancer Research - Exhibit: Hall D
Breast Cancer Stem Cells and the Epithelial-Mesenchymal Transition
Robert Weinberg, PhD
Whitehead Institute for Biomed
Cambridge, MA
12:00 - 1:35
Lunch
12:30 - 1:35
Case Discussion 1 - Ballroom A
12:30 - 1:35
Basic Science Panel Discussions - Ballroom B
Is Extranuclear Estrogen Receptor (Ir)relevant?
Moderators: Suzanne Fuqua, PhD, Baylor College of Medicine, Houston, TX
and Rachel Schiff, PhD, Baylor College of Medicine, Houston, TX
Extra-nuclear ERalpha and ERbeta signal to breast cancer cell biology
Ellis Levin, MD
UC Irvine Long Beach VA Hospital
Long Beach, CA
Membrane ER in endocrine resistance in the lab and the clinic: should we be convinced?
Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM
1:45 - 2:45
Mini-Symposium 2 - Exhibit Hall D
Host-related Factors in Breast Cancer
Moderator: Peter Ravdin, MD, UT Health Science Center, San Antonio, TX
1:45
Obesity, Insulin Resistance and Insulin
Pamela Goodwin, MD
Mount Sinai Hospital
Toronto, CANADA
2:15
Events in the bone micro-environment: Mechanisms of action of bisphonsphonates and other agents
Theresa Guise, MD
Indiana University
Indianapolis, IN
2:45 - 5:30
General Session 4 (#41-51) - Exhibit Hall D
5:30 - 7:30
Poster Discussion 5 (#501-506) - Ballroom A
5:30 - 7:30
Poster Discussion 6 (#601-607) - Ballroom B
5:30 - 7:30
Poster Session 3 (#3001-3182) - Exhibit Halls A-B
Saturday, 12/12/09
6:45 - 5:45
Registration
7:00 - 9:00
Poster Discussion 7 (#701-709) - Ballroom A
7:00 - 9:00
Poster Discussion 8 (#801-811) - Ballroom B
7:00 - 9:00
Poster Session 4 (#4001-4173) - Exhibit Halls A-B
9:00 - 9:30
Plenary Lecture 3 - Exhibit Hall D
New paradigms in tumor immunotherapy
Tyler Curiel, MD, MPH
UT Health Science Center
San Antonio, TX
9:30 - 11:15
General Session 5 (#61-67) - Exhibit Hall D
11:15 - 12:00
William L. McGuire Memorial Lecture– Exhibit Hall D
Supported by an educational grant from GlaxoSmithKline
International Breast Cancer Research: Launching an Expedition to the Moon
Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM
12:00 - 1:25
Lunch
12:25 - 1:25
Case Discussion 2 - Ballroom A
12:25 - 1:25
Basic Science Panel Discussions - Ballroom B
Can We Measure Tumor Dormancy and Does it Matter?
Moderator: Tyler Curiel, MD, MPH, UT Health Science Center, San Antonio, TX
Cancer Immunoediting: Immunologic Control and Sculpting of Cancer
Robert Schreiber, PhD
Washington University School of Medicine
St. Louis, MO
TBA
1:30 - 3:00
Mini-Symposium 3 - Exhibit Hall D
Local Control and Long-term Survival
Moderators: Jay Harris, MD, Dana-Farber Cancer Institute, Boston, MA and Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center, New York, NY
1:30
Overview of the Randomised Trials of Radiotherapy in Early Breast Cancer
Sarah Darby , PhD
CTSU Oxford University
Oxford, UNITED KINGDOM
2:00
How the ‘4:1 ratio’ will likely change with increasingly effective systemic therapy
Jay Harris, MD
Dana-Farber Cancer Institute
Boston, MA
2:30
Minimizing Local Recurrence: What’s proven, what’s not
Monica Morrow, MD, FACS
Memorial Sloan-Kettering Cancer Center
New York, NY
3:00 - 5:30
General Session 6 (#71-80) - Exhibit Hall D
5:30 - 7:30
Poster Discussion 9 (#901-910) - Ballroom A
5:30 - 7:30
Poster Discussion 10 (#951-959) - Ballroom B
5:30 - 7:30
Poster Session 5 (#5001-5169) - Exhibit Halls A-B
Sunday, 12/13/09
6:45 - 10:30
Registration
7:00 - 8:30
Poster Session 6 (#6001-6174) - Exhibit Halls A-B
8:30 - 10:30
YEAR IN REVIEW - Exhibit Hall D
Moderator: C. Kent Osborne, MD, Baylor College of Medicine, Houston, TX
Implications of Recent Advances in Basic Research
Adrian Lee, PhD
Baylor College of Medicine
Houston, TX
Translational Insights for Clinical Research and Practice
Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN
Early Breast Cancer: 2009
Ian Smith, MD
Royal Marsden Hospital
London, UNITED KINGDOM
Metastatic Breast Cancer
Clifford Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Home
Program Schedule
